This site is intended for Healthcare Professionals only.

‘UK must act swiftly to fend off competition if it wants to build the world’s leading life sciences hub’

Date:

Share post:

The UK must act swiftly to fend off competition if it wants to build the world’s leading life sciences hub, a new report suggests.

A year on from the launch of the government’s life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment.

To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a ‘stronger manufacturing and research infrastructure’, alongside better investment in, access to and uptake of innovative medicines.

It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government’s ‘Life Science Vision’, which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health.

The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included:

  • £68 billion in additional GDP over 30 years, owing to increased R&D investment
  • £16.3 billion additional annual GDP from increased pharmaceutical exports
    • Supporting 85,000 additional jobs
  • Up to 40 per cent decrease in disease burden across the whole UK – for areas like cardiovascular disease, mental health conditions and Cancer.
  • Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.

Richard Torbett, chief executive of the ABPI, said: “The report shows the opportunities that investment in life sciences can bring to UK patients, the NHS and the economy.

“Global competition is fiercer than ever, and the UK is struggling to keep pace with competitors like France and Germany. By prioritizing this sector, building strong research and manufacturing bases and creating policies to improve access to medicines for patients we can be a world leader in ten years. We know government shares this ambition and we urge them to work with us to fulfil the UK’s potential.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

How pharmacists can help children and young people with asthma: 2024 AskAboutAsthma campaign highlights

The 2024 #AskAboutAsthma campaign calls on pharmacists to take an active role in improving asthma management and outcomes...

Huxley Europe relaunches HuxQ10 Capsules with triple certification

The relaunch underscores Huxley Europe's commitment to health and welfare, offering specially developed formulas for users with dietary...

Alastair Buxton outlines vision for Community Pharmacy at Westminster Health Forum

Alastair Buxton, Director of NHS Services at CPE, outlines critical issues and solutions at the Westminster Health Forum,...

Food prices remain UK consumers’ top concern, FSA report finds

Consumers worried about food affordability were more likely to take food safety risks to save money The Food...